NCT04789681 2026-04-16
Canakinumab for the Prevention of Lung Cancer, the Can-Prevent-Lung Trial
M.D. Anderson Cancer Center
Phase 2 Recruiting
Clinical Trials
6 trialsNCT04239157 2026-04-13
A Phase II, Open-Label, Study of Subcutaneous Canakinumab, an Anti-IL-1β Human Monoclonal Antibody, for Patients With Low or Int-1 Risk IPSS/IPSS-R Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia
M.D. Anderson Cancer Center
Phase 2 Recruiting
NCT05467800 2026-03-19
Study of Canakinumab in Patients With Myelofibrosis
Icahn School of Medicine at Mount Sinai
Phase 2 Recruiting
NCT06038526 2026-02-19
Evaluation of Canakinumab in High-Risk Former-Smokers
Ohio State University Comprehensive Cancer Center
Phase 2 Active not recruiting
NCT05641831 2026-01-02
Canakinumab for the Prevention of Progression to Cancer in Patients With Clonal Cytopenias of Unknown Significance, IMPACT Study
Ohio State University Comprehensive Cancer Center
Phase 2 Recruiting
NCT04905316 2025-06-17
CHORUS
Memorial Sloan Kettering Cancer Center
Phase 2 Active not recruiting